Will the Human be Able to Create His Own Micro Body within 20 years?

When I raised the said question after finishing my story “UnderEstimate”, famous Sci-Fi writer Dr. Arvind Dubey (Lucknow, India) said :

Not twenty years from now, its in front of u . Pof Yamanaka from Quoto university in Japan has done it. He introduced four transcription factors in a normal cell of adult mice to convert it into an adult pleuripotant cell, I mean a cell which can create a whole animal. What are these adult pleuripotant cells, of course a micro body. If y any means it can be transported to longer distances, Zeashan’s prophecy turns into a reality. However his perception of micro body is different from this, so what, Jules Verne was also having a different perception for the voyage to the moon, which later turned into the reality later on. Well done Zeashan, congratulations.

Here is the original news

Shinya Yamanaka Reprograms Human Adult Cells

Into Embryonic-like Stem Cells

Breakthrough accelerates new avenues of stem cell research

SAN FRANCISCO, CA – November 20, 2007 – Acclaimed stem cell researcher Shinya Yamanaka, MD, PhD, has reported that he and his Kyoto University colleagues have successfully reprogrammed human adult cells to function like pluripotent embryonic stem cells. Because it circumvents much of the controversy and restrictions regarding generation of embryonic stem cells from human embryos, this breakthrough, reported in the journal Cell, should accelerate the pace of stem cell research.

Last year, Yamanaka, who is also a senior investigator at the Gladstone Institute of Cardiovascular Disease (GICD), reported that he and his Kyoto colleagues had reprogrammed mouse skin cells into pluripotent stem cells, laying the foundation to apply this methodology in human cells.

In this earlier work, published in Cell, Yamanaka and his colleagues identified four genetic factors that resulted in the reprogramming of adult mouse cells into induced pluripotent stem (iPS) cells capable of developing into any kind of cell. This summer, he reported in Nature that these iPS cells could even form a new mouse, making them functionally the same as embyonic stem cells. According to the new research, those same genetic factors used with human adult cells resulted in iPS cells which are nearly indistinguishable from human embryonic stem cells.

“The rapid application of this approach to human cells has dramatically changed the landscape of stem cell science,” said GICD Director Deepak Srivastava, MD. “Dr. Yamanaka's work is monumental in its importance to the field of stem cell science and its potential impact on our ability to accelerate the benefits of this technology to the bedside. Not only does this discovery enable more research, it offers a new pathway to apply the benefits of stem cells to human disease.”

“Dr. Yamanaka and his group have made yet another extremely important contribution to the stem cell field,” said Richard Murphy, interim president of the California Institute for Regenerative Medicine (CIRM). “Their results open the door to generating alternative sources of pluripotent cells from patients, which is a major step forward. However, much work still needs to be done to fully characterize and understand the capacity of these induced pluripotent cells to study and to treat human diseases.”

While Yamanaka's work would seem to eliminate the need for controversial research on human embryos, both he and Srivastava emphasized that research must continue. “We are still a long way from finding cures or therapies from stem cells and we don’t know what processes will be effective,” Yamanaka said.

CIRM's Murphy added, “Dr. Yamanaka's work, which uses viral vectors to introduce into cells pluripotency- associated genes, further emphasizes the critical need we have to continue working with naturally occurring human embryonic stem cells, which remain the gold standard against which all alternative sources of human pluripotent stem cells must be tested.”

According to Yamanaka, the next steps will be to understand how these cells can be differentiated into other types of cells and ultimately how they can be used to study disease models and as potential therapies. “We are now finally in a position to make patient-specific stem cells for therapies without fear of immune-rejection and to make disease-specific stem cells that will reveal the underlying cause of many human diseases” he said.

Prof Shinya Yamanaka